The primary dose limiting toxicity was hypertension.
A cumulative sensory peripheral neuropathy was the principal dose-limiting toxicity (DLT) of TAS-106 at the 6.31 mg/m(2) dose level, which was determined to be the maximum tolerated dose (MTD).
The principal dose-limiting toxicities were diarrhoea and neutropenia.
Severe thrombocytopenia, often associated with severe neutro-penia, was the principal dose-limiting toxicity encountered with both administration schedules.
This study aimed to analyse the principal dose-limiting toxicities of infused 5FU therapy observed in a large cohort of patients treated at a single centre.
The principal dose-limiting toxicities are diarrhoea in Caucasian and myelosuppression in Asian patients (Hirata et al, 1999; Cohen et al, 2002).
When 20 patients were treated with S-1 at three dose levels ranging from 50 70 mg m−2 per day, diarrhoea associated with abdominal discomfort and cramping was the principal dose-limiting toxicity.
Diarrhea is one of the principal dose-limiting toxicities of capecitabine and this is reflected in the study findings, with eribulin being associated with comparatively lower symptom scores for diarrhea as well as a lower proportion of patients reporting worsening diarrhea, and a longer TSW for this symptom.
As expected, myelosuppression, particularly severe thrombo-cytopenia, was the principal dose-limiting toxicity of temozolomide in patients treated with the agent on both Schedules A and B. For patients treated on Schedule B, AGAT inactivation in PBMC was significantly greater in patients who experienced severe thrombocytopenia than in those who did not.
The principal dose-limiting toxicities of the combination therapy were the cutaneous side effect hand foot syndrome, which is characteristic of protracted infused fluoropyrimidines or capecitabine (which was designed to mimic continuous infusion of 5-FU), and neutropenia, which is dose limiting with single-agent paclitaxel.
While cisplatin is used widely in the clinic to treat many tumour types, clinical utility is limited by two major factors: (i) drug resistance, either intrinsic or acquired, and (ii) the principal dose-limiting side effects of nephrotoxicity and neurotoxicity.
